uniQure reported 44.00 percent slowing: uniQure stock fell 40.00 percent

Published on 10/08/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

uniQure stock costs EUR 20.25 on October 8, 2026 versus EUR 20.58, minus 1.60 percent. Barclays cut its target to USD 28.00.

Key points in brief

Das Wichtigste in Kürze

uniQure reported 44.00 percent slowing of Huntington's disease progression at 48 months, but the primary endpoint was not statistically significant.
At 36 months, high-dose data showed 80.00 percent slowing on cUHDRS and 67.00 percent on TFC.
Barclays cut its target from USD 60.00 to USD 28.00 while the Nasdaq-listed stock traded at EUR 20.25 at Lang & Schwarz.
QURE's expected next earnings release is listed for November 9, 2026.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure (NL0010696654) was trading at EUR 20.25 at Lang & Schwarz on October 8, 2026 at 4:08 p.m. CEST, minus 1.60 percent versus the prior close of EUR 20.58. On September 29, 2026, GlobeNewswire reported that AMT-130 showed 44.00 percent slowing of disease progression at 48 months, while Reuters reported that the shares fell 40.00 percent after the update.

Three dated milestones

On July 29, 2026, uniQure reported second-quarter revenue of USD 5.84 million and a net loss of USD 81.06 million, while cash and investments totaled USD 810.30 million, according to the company's earnings-call transcript published by Yahoo Finance. On September 2, 2026, uniQure submitted a Biologics License Application for AMT-130 under the accelerated approval pathway, as listed by MarketBeat. On September 29, 2026, the company released the additional 36-month and 48-month clinical data through GlobeNewswire.

What does the 48-month data change?

The result is mixed rather than uniformly positive. In 12 high-dose patients, cUHDRS showed 44.00 percent slowing versus an updated external control, but the p-value was 0.144 and the primary endpoint did not reach statistical significance, according to Reuters. Total Functional Capacity showed 61.00 percent slowing at the same timepoint, while the updated 36-month analysis showed 80.00 percent slowing on cUHDRS and 67.00 percent on TFC, according to GlobeNewswire. The newer 48-month figures were not part of the FDA application, which was based on the earlier 36-month analysis.

Targets diverge after the update

On October 5, 2026, Barclays cut its rating from Overweight to Equal Weight and reduced its price target from USD 60.00 to USD 28.00, according to MarketBeat. The Nasdaq-listed stock was quoted at USD 22.54 at 10:20 a.m. EDT on October 8, 2026, placing it 68.48 percent below its USD 71.50 52-week high; market capitalization was USD 1.6 billion.

Next date on the calendar

Zacks lists November 9, 2026 as the expected date for uniQure's next earnings release. That date would put the next financial update after the regulatory and durability questions raised by the AMT-130 data.

QURE stays below its yearly high

At Lang & Schwarz, uniQure was trading at EUR 20.25 on October 8, 2026 at 4:08 p.m. CEST, minus 1.60 percent versus the Lang & Schwarz prior close of EUR 20.58 on October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of uniQure stock.